Eton Pharmaceuticals, Inc. (ETON)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 40M 80M 120M Q4 '19: 959K Q1 '20: 558K Q2 '20: 578K Q3 '20: 417K Q4 '20: 39K Q1 '21: 11.8M Q2 '21: 14.9M Q3 '21: 15.8M Q4 '21: 21.8M Q1 '22: 12.1M Q2 '22: 16.4M Q3 '22: 18.8M Q4 '22: 21.3M Q1 '23: 24.4M Q2 '23: 29M Q3 '23: 32.8M Q4 '23: 31.6M Q1 '24: 34.3M Q2 '24: 31.4M Q3 '24: 34.7M Q4 '24: 39M Q1 '25: 48.3M Q2 '25: 58.2M Q3 '25: 70.3M Q4 '25: 80M Q1 '26: 86.9M Q2 '26: 105.6M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

-25M 0 25M 50M 75M Q4 '19: 506K Q1 '20: 3K Q2 '20: -5K Q3 '20: -22K Q4 '20: -397K Q1 '21: 9.9M Q2 '21: 12.8M Q3 '21: 13M Q4 '21: 19M Q1 '22: 10.1M Q2 '22: 11.8M Q3 '22: 13.7M Q4 '22: 14.3M Q1 '23: 16.3M Q2 '23: 21.4M Q3 '23: 23.8M Q4 '23: 21.1M Q1 '24: 22.7M Q2 '24: 18.7M Q3 '24: 20.6M Q4 '24: 23.4M Q1 '25: 28.3M Q2 '25: 34.6M Q3 '25: 36.1M Q4 '25: 42.7M Q1 '26: 47.6M Q2 '26: 61.1M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Income TTM

-30M -20M -10M 0 10M 20M 30M Q2 '18: -10.6M Q3 '18: -10.2M Q4 '18: -10.3M Q1 '19: -14.9M Q2 '19: -15.6M Q3 '19: -18.2M Q4 '19: -18.6M Q1 '20: -19.9M Q2 '20: -21.1M Q3 '20: -22.3M Q4 '20: -27.1M Q1 '21: -12.9M Q2 '21: -10.7M Q3 '21: -10.2M Q4 '21: -1.5M Q1 '22: -11.9M Q2 '22: -11M Q3 '22: -8M Q4 '22: -8.3M Q1 '23: -5.7M Q2 '23: -484K Q3 '23: 1.9M Q4 '23: -1.2M Q1 '24: 542K Q2 '24: -6.3M Q3 '24: -5.2M Q4 '24: -2.6M Q1 '25: -2.3M Q2 '25: -807K Q3 '25: -2.7M Q4 '25: -844K Q1 '26: 2M Q2 '26: 16.3M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-30M -20M -10M 0 10M 20M 30M Q2 '18: -11.1M Q3 '18: -11.2M Q4 '18: -12.7M Q1 '19: -17.1M Q2 '19: -17.3M Q3 '19: -19.4M Q4 '19: -18.3M Q1 '20: -20M Q2 '20: -21.4M Q3 '20: -23M Q4 '20: -28M Q1 '21: -13.8M Q2 '21: -11.1M Q3 '21: -10.7M Q4 '21: -2M Q1 '22: -12.4M Q2 '22: -11.9M Q3 '22: -8.9M Q4 '22: -9M Q1 '23: -6.4M Q2 '23: -234K Q3 '23: 2.2M Q4 '23: -936K Q1 '24: 913K Q2 '24: -6.7M Q3 '24: -5.5M Q4 '24: -3.8M Q1 '25: -4.6M Q2 '25: -4.1M Q3 '25: -6.7M Q4 '25: -4.6M Q1 '26: -1.5M Q2 '26: 12.7M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 20M 40M 60M Q4 '20: 696K Q1 '21: 2.2M Q2 '21: 2.3M Q3 '21: 2.8M Q4 '21: 2.8M Q1 '22: 2M Q2 '22: 4.6M Q3 '22: 5.2M Q4 '22: 6.9M Q1 '23: 8M Q2 '23: 7.6M Q3 '23: 9M Q4 '23: 10.6M Q1 '24: 11.6M Q2 '24: 12.7M Q3 '24: 14.1M Q4 '24: 15.6M Q1 '25: 20.1M Q2 '25: 23.6M Q3 '25: 34.2M Q4 '25: 37.2M Q1 '26: 39.3M Q2 '26: 44.5M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-24M -16M -8M 0 8M 16M 24M Q3 '18: -7.4M Q4 '18: -8.1M Q1 '19: -13.1M Q2 '19: -15M Q3 '19: -16M Q4 '19: -18M Q1 '20: -18.5M Q2 '20: -17.1M Q3 '20: -19M Q4 '20: -22.3M Q1 '21: -11.4M Q2 '21: -8.9M Q3 '21: -6.8M Q4 '21: -4.7M Q1 '22: -7.2M Q2 '22: -4.4M Q3 '22: -3.1M Q4 '22: 4.8M Q1 '23: 2M Q2 '23: 6.7M Q3 '23: 9.3M Q4 '23: 6.8M Q1 '24: 5.9M Q2 '24: 42K Q3 '24: 2.1M Q4 '24: 969K Q1 '25: 5.5M Q2 '25: 12.2M Q3 '25: 21.3M Q3 '18 Q3 '19 Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25

Free Cash Flow TTM

-24M -16M -8M 0 8M 16M 24M Q3 '18: -7.6M Q4 '18: -8.4M Q1 '19: -13.6M Q2 '19: -16.2M Q3 '19: -17.1M Q4 '19: -19.1M Q1 '20: -19.2M Q2 '20: -17.2M Q3 '20: -19.1M Q4 '20: -22.4M Q2 '22: -4.4M Q3 '22: -3.2M Q4 '22: 4.8M Q1 '23: 2M Q2 '23: 6.7M Q3 '23: 9.3M Q4 '23: 6.8M Q1 '24: 5.9M Q2 '24: 28K Q3 '24: 2.1M Q4 '24: 943K Q1 '25: 5.5M Q2 '25: 12.2M Q3 '25: 21M Q1 '19 Q4 '19 Q3 '20 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '20: 18.1M Q2 '20: 21M Q1 '21: 26.5M Q2 '21: 25.2K Q3 '21: 25.3M Q1 '22: 25.3M Q2 '22: 25.1M Q3 '22: 25.4M Q1 '23: 25.5K Q2 '23: 26K Q3 '23: 25.7K Q1 '24: 25.8K Q2 '24: 25.8K Q3 '24: 26.6M Q1 '25: 26.9M Q2 '25: 26.9M Q3 '25: 26.9M Q1 '26: 31.5M Q2 '26: 32.8M Q1 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q2 '18: -3.65 Q3 '18: -3.30 Q4 '18: -4.73 Q1 '19: -4.10 Q2 '19: -3.49 Q3 '19: -3.12 Q4 '19: -1.03 Q1 '20: -1.11 Q2 '20: -1.16 Q3 '20: -1.19 Q4 '20: -1.36 Q1 '21: -0.67 Q2 '22: -0.46 Q3 '22: -0.34 Q4 '22: -0.36 Q2 '25: -0.17 Q3 '25: -0.26 Q4 '25: -0.17 Q1 '26: -0.06 Q2 '26: 0.39 Q3 '18 Q2 '19 Q1 '20 Q4 '20 Q3 '22 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.